Docosahexaenoic Acid (DHA) Bioavailability in Humans after Oral Intake of DHA-Containing Triacylglycerol or the Structured Phospholipid AceDoPC®

International audienceAceDoPC((R)) is a structured glycerophospholipid that targets the brain with docosahexaenoic acid (DHA) and is neuroprotective in the experimental ischemic stroke. AceDoPC((R)) is a stabilized form of the physiological 2-DHA-LysoPC with an acetyl group at the sn1 position; preventing the migration of DHA from the sn2 to sn1 position. In this study we aimed to know the bioavailability of C-13-labeled DHA after oral intake of a single dose of C-13-AceDoPC((R)), in comparison with C-13-DHA in triglycerides (TAG), using gas chromatography/combustion/isotope ratio mass spectrometry (GC/C/IRMS) to assess the C-13 enrichment of DHA-containing lipids. C-13-DHA enrichment in plasma phospholipids was significantly higher after intake of AceDoPC((R)) compared with TAG-DHA, peaking after 24 h in both cases. In red cells, C-13-DHA enrichment in choline phospholipids was comparable from both sources of DHA, with a maximum after 72 h, whereas the C-13-DHA enrichment in ethanolamine phospholipids was higher from AceDoPC((R)) compared to TAG-DHA, and continued to increase after 144 h. Overall, our study indicates that DHA from AceDoPC((R)) is more efficient than from TAG-DHA for a sustained accumulation in red cell ethanolamine phospholipids, which has been associated with increased brain accretion

Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients: DHA amends platelet function and redox status

International audiencePlatelets from patients with type 2 diabetes are characterized by hyperactivation and high level of oxidative stress. Docosahexaenoic acid (DHA) may have beneficial effects on platelet reactivity and redox status. We investigated whether moderate DHA supplementation, given as a triglyceride form, may correct platelet dysfunction and redox imbalance in patients with type 2 diabetes. We conducted a randomized, double-blind, placebo-controlled, two-period crossover trial (n=11 post-menopausal women with type 2 diabetes) to test the effects of 400 mg/day of DHA intake for 2 weeks on platelet aggregation, markers of arachidonic acid metabolism, lipid peroxidation status, and lipid composition. Each 2 week-period was separated from the other by a 6-week washout. Daily moderate dose DHA supplementation resulted in reduced platelet aggregation induced by collagen (-46.5%, p<0.001), and decreased platelet thromboxane B2 (-35%, p<0.001), urinary 11-dehydro-thromboxane B2 (-13.2%, p<0.001) and F2-isoprostane levels (-19.6%, p<0.001) associated with a significant increase of plasma and platelet vitamin E concentrations (+20% and +11.8%, respectively, p<0.001). The proportions of DHA increased both in plasma lipids and in platelet phospholipids. After placebo treatment, there was no effect on any parameters tested. Our findings support a significant beneficial effect of low intake of DHA on platelet function and a favorable role in reducing oxidative stress associated with diabetes

Impact of 18F-fluorodeoxyglucose Positron Emission Tomography Response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy : a prospective study from the group d'Etudes des lymphomes de l'adulte and GOELAMS.

International audienc

A dietary supplement to improve the quality of sleep: a randomized placebo controlled trial

<p>Abstract</p> <p>Background</p> <p>To evaluate the effect of a dietary supplement containing polyunsaturated fatty acids, in association with <it>Humulus lupulus </it>extract, on the quality of sleep using the Leeds sleep evaluation questionnaire (LSEQ) in subjects with moderate to severe sleep disorders.</p> <p>Methods</p> <p>Randomized placebo-controlled trial, in a Population-based setting. Participants were adult patients 25 to 65 years old with a chronic primary insomnia who volunteered for the study. The tested intervention consisted of two soft gelatine capsules per day, containing either the dietary supplement (active group) or olive oil (placebo group) for a month. Subjects could also volunteer for two ancillary studies on melatonin and actigraphy. Evaluation criteria included i) perception of the quality of sleep at the end of treatment using the LSEQ questionnaire, ii) sleep efficiency measured by one-week actigraphic movement measurement performed before and during the treatment in a subsample of subjects, iii) night melatonin and 6 sulfatoxymelatonin (aMT6S) urine rates in a subsample of subjects.</p> <p>Results</p> <p>The average of Leeds score was similar in both groups (p = 0.95). A marked improvement in the quality of sleep was observed in both placebo (62%) and active (65%) group (p = 0.52). The evolution of urinary melatonin, aMT6S, and of the Mel/aMT6S ratio showed no differences between the two groups. Sleep efficiency, as measured by actigraphy, improved similarly in both groups during the treatment period, from 72% to 76% and 75% in the active and placebo group respectively (p = 0.91).</p> <p>Conclusions</p> <p>The dietary supplement had neither effect on the perceived quality of sleep, nor on the melatonin metabolism and sleep-wake cycle.</p> <p>Trial registration: clinical trials.gov:NCT00484497</p

Identification of three clinical neurofibromatosis 1 subtypes: Latent class analysis of a series of 1351 patients

International audienc

Identification of three clinical neurofibromatosis 1 subtypes: Latent class analysis of a series of 1351 patients

International audienc